Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas-Reference-Cited by-同舟云学术

Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas

Published:2024-05 Issue: Volume:194 Page:110185
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Yu Kelvin Ken,Yeo Adam^ORCID,Ngan Samuel,Chu Julie^ORCID,Chang David^ORCID,Siva Shankar,Wong Aaron^ORCID,Kron Tomas,Hardcastle Nicholas,Gaudreault Mathieu,Chesson Therese,Williams Siena,Burns Mark^ORCID,Chander Sarat^ORCID

Funder

Australia and New Zealand Sarcoma Association

Publisher

Elsevier BV

Reference21 articles.

1. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution;Lewis;Ann. Surg.,1998

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol.,2014

3. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial;Seddon;Lancet Oncol.,2017

4. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial;Tap;Lancet Oncol.,2017

5. Retroperitoneal sarcomas-a challenging problem;Kumar;Indian J. Surg. Oncol.,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Leiomyosarcoma: A Clinical Case Report;Cureus;2024-09-03

2. Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas. In regard to Yu et al.;Radiotherapy and Oncology;2024-08